‘If I had known cancer was linked to implants, I would never have gotten them’

Some women have been diagnosed with BIA-ALCL, a rare type of lymphoma. There have been 600 reported cases worldwide, with 17 deaths.
Source: Washington Post: To Your Health - Category: Consumer Health News Authors: Source Type: news

Related Links:

Publication date: Available online 22 February 2020Source: Reproductive BioMedicine OnlineAuthor(s): Andrea BUSNELLI, Amerigo VITAGLIANO, Laura MENSI, Stefano ACERBONI, Alessandro BULFONI, Francesca FILIPPI, Edgardo SOMIGLIANAAbstractSeveral epidemiological studies investigated the effects of cancer therapies on fertility. However, conflicting data have been reported.The present systematic review and meta-analysis aims to determine the chances of childbirth in women survived from different types of cancer.We systematically searched Pubmed, MEDLINE, Embase and Scopus, from database inception to July 17, 2019, for published ...
Source: Reproductive BioMedicine Online - Category: Reproduction Medicine Source Type: research
ConclusionPRS was associated with increased risk of FL, but improved overall survival.
Source: Cancer Epidemiology - Category: Cancer & Oncology Source Type: research
ConclusionsWe confirm the high prevalence of ID and anemia in cancer patients. ID status is correlated to tumor response providing a strong rationale for iron monitoring during cancer management.
Source: Supportive Care in Cancer - Category: Cancer & Oncology Source Type: research
ConclusionWhile reduced impact of a cancer diagnosis on LOLE over time is encouraging, the growing number of cancer survivors in Australia is likely to pose complex challenges for cancer patients, their care givers, and health-care systems.
Source: Cancer Epidemiology - Category: Cancer & Oncology Source Type: research
ConclusionsThe xanthone-doxorubicin combination showed promising in vitro activity against lymphoma cells. The results also indicate that the TTX and doxorubicin combination's effect was due to the interaction between TTX with Raf-1 and c-Jun N-kinase receptors, 2 determinants of doxorubicin resistance progression.
Source: Current Therapeutic Research - Category: Drugs & Pharmacology Source Type: research
Publication date: Available online 19 February 2020Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Vasu Saini, Aditi Dhir, Ariana W. Rudnick, Joshua Lukas, Karlo J. Lizarraga, Jason Margolesky, Deborah O. Heros, James E. HoffmanAbstractParaneoplastic neurologic syndromes are rare but well described presentation of certain malignancies in both children and adults. Cerebellar dysfunction is a common paraneoplastic presentation and has been previously reported in association with small cell lung cancer, breast cancers, ovarian tumors, renal cell carcinoma, follicular lymphoma, and Hodgkin’s lymphoma. There are ...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
February 10, marked the start of the Give Blood to Give Time partnership. The American Red Cross and the American Cancer Society have joined forces to raise awareness about how ... The post I am... {This is a content summary only. Click the blog post title to continue reading this post, share your comments, browse the blog and more!}
Source: Red Cross Chat - Category: International Medicine & Public Health Authors: Tags: Blood blood donation blood donor donate blood georgia Give Blood to Give Time Hodgkin’s Lymphoma red blood cells redcrossblood.org Stephanie Lai Source Type: news
AbstractAnti ‐programmed cell death 1 (PD‐1) and its ligand (PD‐L1) has emerged as a novel immunotherapy for non‐small cell lung cancer (NSCLC). However, the proportion of patients who may benefit from immunotherapy is limited and the factors sensitive or resistant to immunotherapy are not completely cle ar. Therefore, to identify reliable biomarkers as predictors of clinical response and resistance to anti‐PD‐1/PD‐L1 therapies have become increasingly important. Here, we report a case of a patient with bone metastatic NSCLC, who achieved a pathologic complete response after preoperative pembr olizumab treatm...
Source: Thoracic Cancer - Category: Cancer & Oncology Authors: Tags: CASE REPORT Source Type: research
Conclusion: The miR-1323 promoted LUAD migration through inhibiting Cbl-b expression. High miR-1323 expression predicted poor prognosis in LUAD patients.
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
(Walter and Eliza Hall Institute) Australian researchers have revealed a new vulnerability in lymphomas that are driven by one of the most common cancer-causing changes in cells. The team, led by Professor Suzanne Cory AC, hopes that this could be a new target for treating a range of cancers.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news
More News: Cancer | Cancer & Oncology | Health | Lymphoma | Women